Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
AuthorsShnyder, Steven D
Cooper, Phillip A
Jayson, Gordon C
AffiliationCancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, UK. S.D.Shnyder@Bradford.ac.uk
MetadataShow full item record
AbstractBACKGROUND: Previous studies have shown extensive vascularisation surrounding subcutaneously implanted fibres when the duration of the US National Cancer Institute (NCI) hollow fibre assay was prolonged. MATERIALS AND METHODS: The feasibility of adapting the NCI assay for evaluating agents targeting the tumour vasculature was investigated in vitro and in vivo. Finally, in the optimised assay, changes in neovasculature formation around the fibres following treatment with the anti-vascular agent paclitaxel were quantified by immunohistochemistry. RESULTS: Correlations between cell number seeded, time in culture and vascular endothelial growth factor (VEGF) secretion were seen. In vivo studies showed that transplanting single rather than 3 fibres at a site reduced inflammation, reducing the length of the fibre transplanted, as did without any significant loss in cell growth over 21 days. A statistically significant reduction in neovascularisation surrounding the fibres was seen accompanying paclitaxel treatment. CONCLUSION: Modifications made here to the NCI hollow fibre assay demonstrate its potential for analysing anti-tumour vasculature agents.
CitationDevelopment of a modified hollow fibre assay for studying agents targeting the tumour neovasculature., 25 (3B):1889-94 Anticancer Res.
- A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
- Authors: Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R
- Issue date: 2007 Apr 15
- The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
- Authors: Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R
- Issue date: 2006 Mar 15
- Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
- Authors: Oh HK, Ha JM, O E, Lee BH, Lee SK, Shim BS, Hong YK, Joe YA
- Issue date: 2007 May 15
- Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
- Authors: Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K, Kolinsky K, Higgins B, Koutcher JA
- Issue date: 2006 Aug
- Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
- Authors: Hsu SC, Ou CC, Chuang TC, Li JW, Lee YJ, Wang V, Liu JY, Chen CS, Lin SC, Kao MC
- Issue date: 2009 Aug 18